Any current/future capex/capital investment/strategic investment?

Alkem Laboratories is commissioning a CDMO biologic plant (Enzene plant) in the U.S., expected to be operational by Q4 FY2025 or Q1 FY2026. The plant focuses on preclinical to clinical small production, with a capex of around INR 450 crores. The company is incurring some non-material expenses currently on this plant, which are not capitalized yet. For strategic investments, Alkem has shifted from parking funds in fixed deposits to investments in AAA+ rated Non-Convertible Debentures (NCDs) and mutual funds, enabling liquidity for potential M&A opportunities. Alkem is actively looking for

Future growth expectations in sales/revenue/volumes?

Domestic growth expected at 8%-9% annually, with Q4 anticipated to be stronger than earlier quarters. Chronic segment projected to grow faster than the acute segment, increasing its share in the portfolio over the next 3 years. ROW (Rest of the World) markets, excluding U.S. and Chile, showed 30% growth in Q2, with further market filings and strategic partnerships expected to sustain this growth in 2-3 years. U.S. business expected to improve in H2 FY '25 after supply chain challenges caused volume declines; mid-single-digit erosion anticipated annually but better performance expected go

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets improving EBITDA margins by at least 100 basis points annually. For FY '25, EBITDA margin guidance is between 18.5% to 19%, with a 100 basis points improvement expected over the previous year. Net profit for Q2 FY '25 grew by 11% year-on-year, and H1 net profit grew 36% Y-o-Y to INR 12,338 million. The company anticipates mid-single-digit top-line growth for the full year despite H1 challenges, especially in the U.S. market. Domestic market growth is expected at 8-9% annually, with Q4 anticipated to deliver stronger growth. Margin expansion driven by a better product mix, c

Current/ Expected Orderbook/ Pending Orders?

The Enzene U.S. plant is progressing as planned, with expected production start by Q4 FY25 to Q1 FY26. The company has already started receiving queries and some orders for the Enzene plant even before production begins. Vikas Gupta mentioned an existing order book based on the plant's progress, indicating a promising pipeline. While detailed specifics on the full orderbook size are not disclosed, the management expressed optimism about upcoming launches and order inflow. Focus on new product launches, including a product with 180-day exclusivity and sacubitril-valsartan, suggests growing pend

Any current/future new fundraising through debt or equity?

There is no mention in the transcript of any current or planned fundraising through debt or equity. The company has increased its cash position significantly, nearly doubling it to around INR 4,250 crores as of September 30, 2024. The raised cash is being strategically invested in marketable instruments to maintain liquidity, partly to support potential M&A opportunities. Management emphasizes a preference for strategic acquisitions rather than purely financially motivated investments. No indications of immediate capital raising via debt or equity were discussed during the call.

IN US

Sale is live|00:00:00left today

Alkem Laboratories LtdQ3 FY24Pharmaceuticals & Biotechnology

Alkem Laboratories Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹5,367P/E: 27.3Market Cap: ₹65.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

→Domestic growth expected at 8%-9% annually, with Q4 anticipated to be stronger than earlier quarters.
→Chronic segment projected to grow faster than the acute segment, increasing its share in the portfolio over the next 3 years.
→ROW (Rest of the World) markets, excluding U.S. and Chile, showed 30% growth in Q2, with further market filings and strategic partnerships expected to sustain this growth in 2-3 years.
→U.S. business expected to improve in H2 FY '25 after supply chain challenges caused volume declines; mid-single-digit erosion anticipated annually but better performance expected going forward.
→New product launches and biosimilars pipeline aimed at driving long-term growth, including plans for 2-3 key biosimilars globally over 5 years.
→Overall, revenue growth for FY '25 expected to be mid-single-digit due to earlier U.S. struggles but improving across other markets.

Margin guidance

Category 2

→The company targets improving EBITDA margins by at least 100 basis points annually.
→For FY '25, EBITDA margin guidance is between 18.5% to 19%, with a 100 basis points improvement expected over the previous year.
→Net profit for Q2 FY '25 grew by 11% year-on-year, and H1 net profit grew 36% Y-o-Y to INR 12,338 million.
→The company anticipates mid-single-digit top-line growth for the full year despite H1 challenges, especially in the U.S. market.
→Domestic market growth is expected at 8-9% annually, with Q4 anticipated to deliver stronger growth.
→Margin expansion driven by a better product mix, cost controls, and higher-margin international markets growth (ROW).
→Focus on strategic M&As to accelerate growth, targeting assets with IRR above 14-15% with strategic synergy benefits.
→Enzene U.S. plant expected to break even in its first year, contributing to future profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention in the transcript of any current or planned fundraising through debt or equity.
→The company has increased its cash position significantly, nearly doubling it to around INR 4,250 crores as of September 30, 2024.
→The raised cash is being strategically invested in marketable instruments to maintain liquidity, partly to support potential M&A opportunities.
→Management emphasizes a preference for strategic acquisitions rather than purely financially motivated investments.
→No indications of immediate capital raising via debt or equity were discussed during the call.

Order book

Yes

→The Enzene U.S. plant is progressing as planned, with expected production start by Q4 FY25 to Q1 FY26.
→The company has already started receiving queries and some orders for the Enzene plant even before production begins.
→Vikas Gupta mentioned an existing order book based on the plant's progress, indicating a promising pipeline.
→While detailed specifics on the full orderbook size are not disclosed, the management expressed optimism about upcoming launches and order inflow.
→Focus on new product launches, including a product with 180-day exclusivity and sacubitril-valsartan, suggests growing pending orders for U.S. market.

Capex plans

Yes

→Alkem Laboratories is commissioning a CDMO biologic plant (Enzene plant) in the U.S., expected to be operational by Q4 FY2025 or Q1 FY2026. The plant focuses on preclinical to clinical small production, with a capex of around INR 450 crores.
→The company is incurring some non-material expenses currently on this plant, which are not capitalized yet.
→For strategic investments, Alkem has shifted from parking funds in fixed deposits to investments in AAA+ rated Non-Convertible Debentures (NCDs) and mutual funds, enabling liquidity for potential M&A opportunities.
→Alkem is actively looking for M&A opportunities that are strategic, where they can add value and build synergies; they target IRRs above 14-15%, with a cost of capital around 12%.
→The company has also invested about INR 30 crores in a strategic but low-risk company investment.

How does Alkem Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alkem Laboratories Ltd

Rev 4Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alkem Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio